Do VEDs and PDE5 Inhibitors Increase Nighttime Tumescence?
PDE5 inhibitors improve nocturnal penile tumescence (NPT), while vacuum erection devices (VEDs) do not significantly affect NPT despite improving overall erectile function.
PDE5 Inhibitors and Nocturnal Tumescence
PDE5 inhibitors have demonstrated improvement in nocturnal penile tumescence and rigidity in clinical studies 1. The mechanism relates to their effect on endothelial function—by enhancing nitric oxide-mediated vasodilation, PDE5 inhibitors improve the physiologic erectile responses that occur during REM sleep. This improvement in NPT serves as an objective marker of the drug's systemic effect on erectile tissue health beyond just facilitating on-demand erections.
The evidence shows that PDE5i therapy results in measurable improvements in NPT testing alongside other markers of erectile function 1. This is particularly relevant when considering these medications for penile rehabilitation protocols, as the enhancement of spontaneous nighttime erections may help preserve cavernosal tissue oxygenation and prevent fibrosis.
Vacuum Erection Devices and Nocturnal Tumescence
In contrast, VEDs do not improve nocturnal penile tumescence 2. A 2019 study directly comparing VED combined with tadalafil versus tadalafil alone found no significant difference in NPT testing between the two groups, despite the combination therapy showing superior outcomes in other erectile function measures (IIEF-5 scores, penile length preservation, and successful vaginal penetration rates) 2.
This finding makes physiologic sense: VEDs work through mechanical negative pressure applied during waking hours to draw blood into the corpora cavernosa. They cannot influence the spontaneous, neurologically-mediated erections that occur during sleep. VEDs improve erectile function through regular use and tissue stretching, but this benefit does not translate to enhanced nighttime tumescence.
Clinical Implications
When NPT Testing Matters
Both the 2025 EAU guidelines and 2018 AUA guidelines list nocturnal penile tumescence and rigidity testing as a specialized diagnostic test indicated for 3, 4:
- Primary ED (not caused by acquired organic disease)
- Young patients with pelvic/perineal trauma
- Complex psychiatric or psychosexual disorders
- Medicolegal documentation
Treatment Selection Based on Mechanism
For improving NPT specifically: PDE5 inhibitors are the evidence-based choice, particularly daily dosing regimens that maintain steady-state drug levels 1
For overall erectile rehabilitation: Combination therapy with VED plus PDE5i provides superior outcomes compared to either alone, with improvements in IIEF-5 scores, penile length preservation, and intercourse success rates—even though NPT remains unchanged 2, 5
Important Caveat
The lack of NPT improvement with VEDs should not discourage their use. VEDs remain highly effective for erectile dysfunction treatment with pooled efficacy rates of 80% for successful intercourse across multiple etiologies 6. The 2018 AUA guidelines provide a moderate recommendation for VED use, and the 2025 EAU guidelines note that VED combined with daily tadalafil shows enhanced results in multimodal ED treatment approaches 3, 4.
The distinction is that VEDs improve functional erectile capacity through mechanical and rehabilitative mechanisms, while PDE5 inhibitors enhance both functional erections and the underlying physiologic erectile responses including NPT.